Mucoviscidose : le tournant des modulateurs
(2019) Louvain médical — Vol. 138, n° 2, p. 126-136 (2019)
Files
LebecqueOLouvMed2019.pdf
Open Access - Adobe PDF
- 324.75 KB
Details
- Authors
- Abstract
- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are small molecules aimed at improving CFTR function by specifically targeting the different classes of CFTR mutations. Recent Phase II studies of triple therapy, including new generation correctors, have demonstrated spectacular improvements in forced expiratory volume in 1s (FEV1), likely to translate into improved quality of life and increased life expectancy. Within the next 5 years, a highly effective CFTR modulator therapy will probably be approved for most cystic fibrosis patients, including those carrying at least one copy of the F508del mutation (88% of Belgian patients). Patients with well-preserved lungs will benefit most from these treatments.
- Affiliations
Citations
Lebecque, O., Leal, T., & Lebecque, P. (2019). Mucoviscidose : le tournant des modulateurs. Louvain médical, 138(2), 126-136. https://hdl.handle.net/2078.5/171143 (Original work published 2019)